Encare Biotech is a spin-off of Utrecht UMC. Their lead product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin.

EnCare Biotech aims to develop a new therapeutic antibody for the prevention of heart failure after acute myocardial infarction (heart attack).

Company: Encare Biotech
Fund: II
Status: active
Team member: Harrold van Barlingen
Technology: Therapeutics
Website: encarebiotech.com